Crinetics Pharmaceuticals, Inc.: 5%+ holders

As of November 6, 2026, 6 holders' latest Schedule 13D or 13G filings report owning 5% or more of Crinetics Pharmaceuticals, Inc. The largest reported stake is Dapice Joshua J.'s, at 8.5%. 12 filings are on record since August 12, 2025 (Schedule 13G/A, February 5, 2026).

DRIEHAUS CAPITAL MANAGEMENT LLC also filed stake reports on 16 other companies ↓

Sell to companies like Crinetics Pharmaceuticals, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.

Your website Find my buyers

Opens in a new tab. No signup.

Key facts

• Filed 2026-08-13 · Holder: Wellington Management Group LLP · Percent: 6.8% · SCHEDULE 13G/A
• Filed 2026-08-07 · Holder: Fmr LLC · Percent: 1.4% · SCHEDULE 13G/A
• Filing 2026-08-03 · Reporting person: Farallon Capital Management, L.L.C. · Sole voting: 0 · Shared voting: 8,989,098 · Sole dispositive: 0 · Shared dispositive: 8,989,098 · SCHEDULE 13G/A, 2026-08-03
• Filed 2026-05-15 · Holder: T. Rowe Price Associates, Inc. · Percent: 5.1% · SCHEDULE 13G/A
• Filed 2026-05-15 · Holder: Wellington Management Group LLP · Percent: 7.8% · SCHEDULE 13G/A

Crinetics Pharmaceuticals, Inc. has 12 Schedule 13D or 13G filings on record since 2025-08-12. 6 holders' latest filing reports 5% or more of common stock. Each figure below is the holder's own, as filed, with the filing linked.

Holders

Swipe the table sideways to see every column.

Holding shares or following this stake? See who's behind Crinetics Pharmaceuticals, Inc. and the warning signs.

See Crinetics Pharmaceuticals, Inc.'s free Snapshot Watch Crinetics Pharmaceuticals, Inc.: email me the next time it files something

Free to see. No signup.

Keep reading

More on Crinetics Pharmaceuticals, Inc. and the records around it.

Crinetics Pharmaceuticals, Inc. elsewhere on the record

• Who owns it

Companies that share a holder

• DRIEHAUS CAPITAL MANAGEMENT LLC also filed stake reports on 16 other companies: Cardinal Infrastructure Group Inc. (Aug 2026), Cue Biopharma, Inc. (Aug 2026), Definium Therapeutics, Inc. (Aug 2026)
• Farallon Capital Management, L.L.C. also filed stake reports on 18 other companies: EXELIXIS, INC. (Nov 2026), ENANTA PHARMACEUTICALS INC (Aug 2026), InflaRx N.V. (Aug 2026)
• Farallon Capital Partners, L.P. also filed stake reports on 19 other companies: BridgeBio Pharma, Inc. (May 2026), InflaRx N.V. (May 2026), Beta Bionics, Inc. (May 2026)

Want the whole picture on Crinetics Pharmaceuticals, Inc.?

Example from a real report (our sample on Target): “Target eliminated approximately 1,800 corporate positions, with around 1,000 employees receiving layoff notices and the remainder accounted for by eliminating open roles.” Source: NBC News

A Full Report on Crinetics Pharmaceuticals, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.

What the Full Report on Crinetics Pharmaceuticals, Inc. covers

1. The Short Answer

2. Which Company This Is

3. What They Do, And How The Money Works

4. Who Runs It, And How To Reach Them

5. The Money: Funding, Valuation, Runway

6. Who Pays Them, And Who They Are Up Against

7. Warning Bells

8. Sources

   13 cited sources found

Plus the sections for what you are deciding, which you pick after ordering.

Order Full ReportSee a sample report

A real finished report, first screen. Opens in a new tab.

Voting and dispositive power, as filed

Swipe the table sideways to see every column.

The latest filing identifies Crinetics Pharmaceuticals, Inc. by CUSIP 22663K107 and gives its principal executive office as 6055 Lusk Blvd, San Diego (SCHEDULE 13G/A, 2026-08-13).

Timeline

Swipe the table sideways to see every column.

Questions about who owns Crinetics Pharmaceuticals, Inc.

Who owns Crinetics Pharmaceuticals, Inc.?

On this page, 6 holders' latest ownership filings report 5% or more of Crinetics Pharmaceuticals, Inc.: Dapice Joshua J. (8.5%, Schedule 13G/A, filed 2026-02-05), Farallon Capital Management, L.L.C. (8.5%, Schedule 13G/A, filed 2026-08-03), Wellington Management Group LLP (6.8%, Schedule 13G/A, filed 2026-08-13), Driehaus Capital Management LLC (6.11%, Schedule 13G/A, filed 2026-05-15) and Vanguard Capital Management (5.19%, Schedule 13G, filed 2026-04-29); 1 more is listed above.

Who are the largest shareholders of Crinetics Pharmaceuticals, Inc.?

By the share each holder's latest filing reports, the largest holders of Crinetics Pharmaceuticals, Inc. on this page are Dapice Joshua J. (8.5%), Farallon Capital Management, L.L.C. (8.5%) and Wellington Management Group LLP (6.8%).

When did Dapice Joshua J. buy into Crinetics Pharmaceuticals, Inc.?

The filings give report dates, not purchase dates. The earliest filing from Dapice Joshua J. on this page is the Schedule 13G, filed 2025-09-08, reporting 6%; its latest, Schedule 13G/A filed 2026-02-05, reports 8.5%.

Is this an audit or a full list?

Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 12 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.

Also on the record for Crinetics Pharmaceuticals, Inc.

Swipe the table sideways to see every column.

Tools for this story

Each opens in a new tab, filled in for Crinetics Pharmaceuticals, Inc.. With no account yet, you sign up free and land on the result.

• Get an alert when Crinetics Pharmaceuticals, Inc. is mentioned again
• Find former Crinetics Pharmaceuticals, Inc. employees to interview
• Verify a claim or statistic

Where this comes from

Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.

Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.

All recent stakesThat week's stakes